VEGF Inhibitors From Macular Edema to Diabetic Retinopathy
21 September 2021
6:30 PM, CEST
Program:
Chairs:
Stanislao Rizzo
Federico Ricci
Pathophysiology of diabetic retinopathy: the role of vascular growth factor
Federico Ricci
Evidence that DME sustained treatment with VEGF inhibitors improves severity and progression of diabetic retinopathy
Alessandro Invernizzi
Pros: Angelo Minnella
Cons: Massimo Nicolò
VEGF inhibitors in non-proliferative diabetic retinopathy as prevention of sight-threatening complications
Marco Lupidi
Pros: Edoardo Midena
Cons: Monica Varano
Pharmacological treatment of proliferative diabetic retinopathy in 2021
Francesco Viola
Pros: Giovanni Staurenghi
Cons: Francesco Bandello
Role of pharmacological therapy of vitreous hemorrhage from PDR after Protocol AB
Daniele Veritti
Pros: Paolo Lanzetta
Cons: Francesco Boscia
Closing remarks
Stanislao Rizzo
Discussion
